Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecular PD-L1 PET/CT Imaging with 89Zr-atezolizumab in metastatic Triple Negative Breast Cancer
2022-500808-21-00Phase 2Completed
- Sponsor
- Karolinska University Hospital
- Start
- Dec 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab, 89Zr-atezolizumab, nab-paclitaxel and carboplatin in triple-negative breast cancer (TNBC) (3 arms), sponsored by Karolinska University Hospital. Primary endpoint: Agreement between PD-L1 IHC and PD-L1 PET/CT (Cohen’s kappa). Started Dec 2022; status: completed.
02
Drugs
atezolizumab89Zr-atezolizumabnab-paclitaxelcarboplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2022-500808-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500808-21-00.